Adeoye Y Olukotun
CIK 1242615 · Chief Medical Officer · last filed 2026-08-20
Adeoye Y Olukotun is a Chief Medical Officer who has filed 50 SEC Form 4 insider transactions across 6 companies since 2007. The most recent filing shows the insider sold $173.9K of ARWR on Aug 20, 2026. Across all open-market trades the lifetime net is −$1.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ARWR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
695 KMS PL
ANN ARBOR, MI 48108
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARWR | Director | 31,600 | $58.16 | $1.84M | -$1.88M | 13 | 2026-08-20 |
| TNXP | Director | 0 | $4.74 | $0 | $5.0K | 11 | 2026-05-14 |
| BIOCLINICA INC (BIOC) Delisted | Director | 0 | $0.43 | $0 | $0 | 3 | 2013-03-14 |
| ICAGEN INC (ICGN) Delisted | Director | 0 | — | — | $0 | 11 | 2011-10-28 |
| BIOCLINICA INC (UWBK) Delisted | Director | — | — | — | $0 | 3 | 2010-05-13 |
| VIA Pharmaceuticals, Inc. (VIAP) Delisted | Chief Medical Officer | 59,624 | — | — | $0 | 3 | 2007-12-19 |
Recent Filings
50 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-20 | ARWR | Sell (S) | −2,000 | -$173.9K | EDGAR |
| 2026-08-18 | ARWR | Notice (144) | −2,000 | -$173.9K | EDGAR |
| 2026-05-14 | TNXP | Grant (A) | — | $0 | EDGAR |
| 2025-12-23 | ARWR | Sell (S) | −10,000 | -$676.6K | EDGAR |
| 2025-12-19 | ARWR | Notice (144) | −10,000 | -$676.6K | EDGAR |
| 2025-12-18 | ARWR | Grant (A) | +7,819 | $0 | EDGAR |
| 2025-05-15 | TNXP | Grant (A) | — | $0 | EDGAR |
| 2025-02-28 | TNXP | Other (J) | −0 | -$2 | EDGAR |
| 2025-01-27 | ARWR | Sell (S) | −959 | -$20.1K | EDGAR |
| 2025-01-23 | ARWR | Notice (144) | −959 | -$20.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.